Slingshot members are tracking this event:

Allergan's (AGN) XEN Gel Stent Approved by FDA to Reduce Intraocular Pressure (IOP) in Treatment-Resistant Glaucoma Patients

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 22, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Xen Gel Stent, Intraocular Pressure, Glaucoma, Treatment-resistant